Note: This document contains side effect information about delavirdine. Some of the dosage forms listed on this page may not apply to the brand name Rescriptor.
Common side effects of Rescriptor include: skin rash and nausea. Other side effects include: diarrhea, fatigue, headache, increased serum alanine aminotransferase, and increased serum aspartate aminotransferase. See below for a comprehensive list of adverse effects.
Applies to delavirdine: oral tablet
Along with its needed effects, delavirdine (the active ingredient contained in Rescriptor) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor as soon as possible if any of the following side effects occur while taking delavirdine:
Some side effects of delavirdine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to delavirdine: oral tablet
In clinical trials with this drug alone or with other antiretroviral agents, most side effects were of mild or moderate severity. The most common drug-related side effect was skin rash.
Most drug-related rashes occurred within 1 to 3 weeks after starting therapy. In most cases, rash duration was less than 2 weeks and did not require dose reduction or discontinuation of this drug. Most patients resumed therapy after rechallenge with this drug when treatment was interrupted due to rash. The distribution of rash was primarily on the upper body and proximal arms, with decreasing severity of lesions on the neck and face, and progressively less on the remaining trunk and limbs.
Erythema multiforme and Stevens-Johnson syndrome occurred rarely in clinical trials and typically resolved when this drug was discontinued.
Very common (10% or more): Rash (included rash, maculopapular rash, urticaria; 35.4%), rashes (up to 19.5%), grade 1 rash (erythema, pruritus; 16.7%), grade 2 rash (diffuse maculopapular rash, dry desquamation; 14.3%)
Common (1% to 10%): Grade 3 rash (vesiculation, moist desquamation, ulceration)
Frequency not reported: Epidermal cyst, sebaceous cyst, angioedema, dermal leukocytoclastic vasculitis, dermatitis, desquamation, diaphoresis, discolored skin, dry skin, erythema, erythema multiforme, folliculitis, fungal dermatitis, hair loss, herpes zoster/simplex, nail disorder, petechiae, non-application site pruritus, seborrhea, skin hypertrophy, skin disorder, skin nodule, Stevens-Johnson syndrome, urticaria, vesiculobullous rash, wart
Very common (10% or more): Nausea (up to 20.3%)
Common (1% to 10%): Vomiting, diarrhea, generalized abdominal pain, increased amylase
Frequency not reported: Abdominal cramps, abdominal distention, localized abdominal pain, lip edema, bloody stool, colitis, constipation, Clostridium difficile associated diarrhea, diverticulitis, dry mouth, dyspepsia, dysphagia, enteritis (at all levels), eructation, fecal incontinence, flatulence, gagging, gastroenteritis, gastroesophageal reflux, gastrointestinal bleeding, gastrointestinal disorder, gingivitis, gum hemorrhage, increased lipase, increased saliva, mouth/tongue ulcers/inflammation, oral/enteric moniliasis, pancreatitis, rectal disorder, sialadenitis, tooth abscess, toothache, gastritis
Increased amylase (greater than 2 times the upper limit of normal [2 x ULN]) has been reported in up to 3.5% of patients.
Very common (10% or more): Headache (up to 16.8%)
Frequency not reported: Abnormal coordination, amnesia, cognitive impairment, confusion, disorientation, dizziness, hyperesthesia, hyperreflexia, hypertonia, hypesthesia, impaired concentration, migraine, neuropathy, nystagmus, paralysis, parosmia, restlessness, sleep cycle disorder, somnolence, taste perversion, tinnitus, tingling, tremor, vertigo
Very common (10% or more): Asthenia/fatigue (up to 16%)
Common (1% to 10%): Fever, influenza syndrome, localized pain
Frequency not reported: Abscess, chills, generalized/localized edema, infection, viral infection, malaise, Mycobacterium tuberculosis infection, increased thirst, increased serum alkaline phosphatase, increased/decreased weight, weakness, ear pain, otitis media
Very common (10% or more): Depressive symptoms (up to 12.6%)
Common (1% to 10%): Anxiety, insomnia
Frequency not reported: Agitation, change in dreams, decreased libido, emotional lability, euphoria, hallucination, manic symptoms, nervousness, paranoid symptoms
Decreased neutrophils (less than 750/mm3), decreased hemoglobin (less than 7 mg/dL), prolonged prothrombin time (greater than 1.5 x ULN), and increased activated partial thromboplastin (greater than 2.33 x ULN) have been reported in up to 7.6%, up to 2.9%, up to 2.4%, and up to 2.4% of patients, respectively.
Common (1% to 10%): Decreased neutrophils, decreased hemoglobin, prolonged prothrombin time, increased activated partial thromboplastin
Frequency not reported: Adenopathy, bruising, eosinophilia, granulocytosis, leukopenia, pancytopenia, purpura, spleen disorder, thrombocytopenia
Postmarketing reports: Hemolytic anemia
Common (1% to 10%): Upper respiratory infection, sinusitis, bronchitis, cough, pharyngitis
Frequency not reported: Chest congestion, dyspnea, epistaxis, hiccups, laryngismus, pneumonia, rhinitis
Common (1% to 10%): Increased ALT, increased AST, increased bilirubin, increased GGT
Frequency not reported: Hepatomegaly, jaundice, bilirubinemia, nonspecific hepatitis
Postmarketing reports: Hepatic failure
Increased ALT (greater than 5 x ULN), AST (greater than 5 x ULN), bilirubin (greater than 2.5 x ULN), and GGT (greater than 5 x ULN) have been reported in up to 5.1%, up to 3.4%, up to 2.5%, and up to 1.8% of patients, respectively.
Decreased or increased glucose (hypoglycemia [less than 40 mg/dL] or hyperglycemia [greater than 250 mg/dL]) has been reported in up to 1.7% of patients.
Common (1% to 10%): Hyperglycemia/hypoglycemia
Frequency not reported: Alcohol intolerance, anorexia, increased/decreased appetite, hyperkalemia, hypertriglyceridemia, hyperuricemia, hypocalcemia, hyponatremia, hypophosphatemia, redistribution/accumulation of body fat
-Frequency not reported: Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance"
Frequency not reported: Abnormal cardiac rate and rhythm, cardiac insufficiency, cardiomyopathy, hypertension, pallor, peripheral vascular disorder, postural hypotension
Frequency not reported: Increased serum creatinine, renal calculi, renal pain
Postmarketing reports: Acute renal failure
Frequency not reported: Amenorrhea, breast enlargement, chromaturia, epididymitis, hematuria, hemospermia, impaired urination, impotence, metrorrhagia, nocturia, polyuria, proteinuria, testicular pain, urinary tract infection, vaginal moniliasis
Frequency not reported: Arthralgia/arthritis of single and multiple joints, bone disorder, bone pain, myalgia, neck rigidity, tendon disorder, tenosynovitis, tetany, muscle cramp
Postmarketing reports: Rhabdomyolysis
Frequency not reported: Blepharitis, blurred vision, conjunctivitis, diplopia, dry eyes, photophobia
Frequency not reported: Immune reconstitution syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)
Frequency not reported: Allergic reaction
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Rescriptor